FDA’s surrogate endpoint table provides valuable information for drug developers on endpoints that may be considered and discussed with FDA for individual development programs.
Similar Posts
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps
SAN DIEGO – August 7, 2025 – Tandem Diabetes Care, Inc. (Nasdaq: TNDM) has announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery.Intravascular PICC Catheter Recall: Bard Removes PowerPICC Intravascular Catheters
This communication is part of the Communications Pilot to Enhance the Medical Device Recall ProgramE6(R3) Good Clinical Practice (GCP)
The Food and Drug Administration is announcing the availability of a final guidance for industry entitled “E6(R3) Good Clinical Practice.” This revision incorporates flexible, risk-based approaches and embraces innovations in trial design, conduct, and technology.Best Buy Bones, Inc. Recalls Nature’s Own Pet Chews Bully Bites Because of Possible Salmonella Health Risk
October 3, 2025, Best Buy Bones, Inc. of Mount Morris, Michigan is recalling four lots of Nature’s Own Pet Chews Bully Bites 1 Pound pet treats in 16 oz. bags with a shared expiration date of September 2027because it has the potential to be contaminated with Salmonella. Salmonella can affect animalsClinical Outcome Assessments (COA) Qualification Program Submissions
Clinical Outcome Assessments (COA) Qualification Program SubmissionsThe Ambriola Company Issues Recall of Cheese Products Because of Listeria Health Risk
The Ambriola Company is recalling select cheese products after routine testing confirmed the presence of Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy in